| Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Colorectal Carcinoma
|
0.800 | GeneticVariation | UNIPROT | ||||||||
Pancreatic carcinoma
|
0.740 | CausalMutation | CLINVAR | ||||||||
Pancreatic carcinoma
|
0.740 | CausalMutation | CLINVAR | ||||||||
Organoid Nevus Phakomatosis
|
0.730 | CausalMutation | CLINVAR | ||||||||
Stomach Neoplasms
|
0.710 | CausalMutation | CLINVAR | ||||||||
NEVUS, EPIDERMAL (disorder)
|
0.710 | CausalMutation | CLINVAR | ||||||||
Multiple Myeloma
|
0.700 | CausalMutation | CLINVAR | ||||||||
Primary low grade serous adenocarcinoma of ovary
|
0.700 | CausalMutation | CLINVAR | ||||||||
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
0.700 | CausalMutation | CLINVAR | ||||||||
increased risk of pancreatic cancer
|
0.700 | CausalMutation | CLINVAR | ||||||||
Nevus Sebaceus of Jadassohn
|
0.700 | CausalMutation | CLINVAR | ||||||||
Neoplasms
|
0.100 | GeneticVariation | BEFREE | 44% of the tumors were positive for G12D, 20% for G12V, and 10% for G12C. | 27591291 | 2016 | |||||
Non-Small Cell Lung Carcinoma
|
0.790 | GeneticVariation | BEFREE | NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation. | 22247021 | 2012 | |||||
Pancreatic Ductal Adenocarcinoma
|
0.020 | GeneticVariation | BEFREE | Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-Ras(G12D) and is characterized by a desmoplastic reaction composed of deregulated, proliferating cells embedded in an abnormal extracellular matrix (ECM). | 23555182 | 2013 | |||||
Lung Neoplasms
|
0.080 | GeneticVariation | BEFREE | Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids. | 25077772 | 2014 | |||||
Carcinogenesis
|
0.100 | GeneticVariation | BEFREE | Tumorigenesis was measured in the Kras(G12D/+);Ptf1a(Cre/+) mouse model of PDA; these mice were crossed with mice with pancreas-specific disruption of genes encoding PI3K p110α (Pik3ca), p110β (Pik3cb), or RAC1 (Rac1). | 25311989 | 2014 | |||||
Childhood Angiosarcoma
|
0.010 | GeneticVariation | BEFREE | Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma. | 27544804 | 2016 | |||||
Hemangiosarcoma
|
0.010 | GeneticVariation | BEFREE | Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma. | 27544804 | 2016 | |||||
Adult Angiosarcoma
|
0.010 | GeneticVariation | BEFREE | Angiosarcoma showed a KRAS G12D point mutation, which is considered to be characteristic of vinyl chloride-induced angiosarcoma. | 27544804 | 2016 | |||||
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 | GeneticVariation | BEFREE | G12D K-Ras increased cleavage of p35 to p25, a stable and greater activator of CDK5, thus implicating a role for CDK5 in early progression of PDAC. | 21825040 | 2011 | |||||
Secondary malignant neoplasm of colon and/or rectum
|
0.030 | GeneticVariation | BEFREE | G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. | 26662311 | 2016 | |||||
Colorectal Carcinoma
|
0.800 | GeneticVariation | BEFREE | G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. | 31309326 | 2019 | |||||
Malignant neoplasm of colon and/or rectum
|
0.060 | GeneticVariation | BEFREE | G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. | 31309326 | 2019 | |||||
Malignant Neoplasms
|
0.100 | GeneticVariation | BEFREE | G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively. | 31554397 | 2019 | |||||
Primary malignant neoplasm
|
0.100 | GeneticVariation | BEFREE | G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively. | 31554397 | 2019 |